BOTOX® (OnabotulinumtoxinA / Botulinum Neurotoxin Type A)
⚠️ Critical Disclaimer: Botulinum toxin type A is an extremely potent biologic neurotoxin, prescription-only drug. This product below is For Research Use Only. Not for human injection, cosmetic or clinical treatment.
Basic Information
- Common Name: BOTOX® (brand name, AbbVie/Allergan)
- Generic: OnabotulinumtoxinA (Botulinum Neurotoxin Type A, Hall strain)
- Complex MW: ~900 kDa full neurotoxin complex; core toxin heavy chain ~100 kDa, light chain ~50 kDa
- Core toxin protein: 150 kDa di-chain protein (heavy chain + zinc metalloprotease light chain linked by disulfide bond)
- Appearance: Sterile vacuum-dried lyophilized white powder
- Solubility: Reconstituted with sterile 0.9% NaCl
- Storage: Lyophilized powder store at 2–8℃, DO NOT FREEZE. Protect from light. After reconstitution, use within short time window; toxin activity degrades quickly.
Important: Activity measured in Mouse LD50 Units, not by weight. Units cannot be interconverted with other botulinum toxin brands.
Development Background
Botulinum neurotoxin type A is produced by fermentation of Clostridium botulinum (Hall strain). BOTOX is the original commercial formulation, first approved medically in 1989, cosmetic indication approved later. It is a large protein toxin, not a short synthetic peptide. SNAP‑8 / Argireline are small cosmetic peptides that mimic its pathway but have completely different mechanism.
Mechanism of Action (Research Findings)
- Heavy chain binds to presynaptic motor nerve terminal receptor and mediates internalization into neuron.
- Disulfide bond reduction releases light chain zinc metalloprotease into cytosol.
- Light chain irreversibly cleaves SNAP‑25 protein (SNARE complex).
- SNARE complex cannot assemble; synaptic vesicles cannot fuse with nerve membrane.
- Acetylcholine release blocked at neuromuscular junction → local reversible muscle paralysis.
- Blockade lasts 3–4 months in human tissue until neuron regenerates new SNAP‑25.
Research Areas
- Neuromuscular junction & SNARE protein biology
- Neurotransmitter exocytosis / vesicle trafficking
- Pain signaling, spasticity, dystonia animal models
- Protein toxin structure & enzyme substrate interaction
- Comparison study vs synthetic SNARE-mimetic peptides (SNAP-8, Argireline)
Key Difference vs SNAP-8
- Botox: Large protein toxin, irreversible cleavage of SNAP-25, strong muscle paralysis, injectable prescription biologic
- SNAP-8: Short synthetic octapeptide, competitive reversible binding only, no protein cleavage, mild inhibition, cosmetic raw material








评价
目前还没有评价